CGON
Income statement / Annual
Last year (2023), CG Oncology, Inc. Common stock's total revenue was $204,000.00,
an increase of 6.81% from the previous year.
In 2023, CG Oncology, Inc. Common stock's net income was -$48.61 M.
See CG Oncology, Inc. Common stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$204,000.00
|
$191,000.00
|
$10.36 M
|
| Cost of Revenue |
$45.75 M |
$15,000.00 |
$10,000.00 |
| Gross Profit |
-$45.55 M |
$176,000.00 |
$10.35 M |
| Gross Profit Ratio |
-223.27 |
0.92 |
1 |
| Research and Development
Expenses |
$45.75 M
|
$29.03 M
|
$18.32 M
|
| General & Administrative
Expenses |
$9.90 M
|
$6.41 M
|
$4.65 M
|
| Selling & Marketing
Expenses |
$0.00
|
-$15,000.00
|
-$10,000.00
|
| Selling, General &
Administrative Expenses |
$9.90 M
|
$6.39 M
|
$4.64 M
|
| Other Expenses |
$0.00 |
-$196,000.00 |
$218,000.00 |
| Operating Expenses |
$55.65 M |
$35.42 M |
$22.95 M |
| Cost And Expenses |
$55.65 M |
$35.44 M |
$22.96 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$1,000.00 |
$451,000.00 |
| Depreciation &
Amortization |
$17,000.00
|
$15,000.00
|
$10,000.00
|
| EBITDA |
-$55.43 M
|
-$35.23 M
|
-$12.38 M
|
| EBITDA Ratio |
-271.73 |
-184.46 |
-1.22 |
| Operating Income Ratio
|
-271.81
|
-184.53
|
-1.22
|
| Total Other
Income/Expenses Net |
$6.84 M
|
-$197,000.00
|
-$233,000.00
|
| Income Before Tax |
-$48.61 M |
-$35.44 M |
-$12.84 M |
| Income Before Tax Ratio
|
-238.27
|
-185.57
|
-1.24
|
| Income Tax Expense |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$48.61 M |
-$35.44 M |
-$12.84 M |
| Net Income Ratio |
-238.27 |
-185.57 |
-1.24 |
| EPS |
-15.65 |
-0.53 |
-0.19 |
| EPS Diluted |
-15.65 |
-0.53 |
-0.19 |
| Weighted Average Shares
Out |
$4.33 M
|
$66.64 M
|
$66.64 M
|
| Weighted Average Shares
Out Diluted |
$4.33 M
|
$66.64 M
|
$66.64 M
|
| Link |
|
|
|
